Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Phthalocyanine-biopolymeric nanoparticle delivery systems for cancer photodynamic therapy

Descrizione del progetto

Miglioramento dell’applicazione della terapia fotodinamica nel trattamento del cancro

La terapia fotodinamica (PDT, PhotoDynamic Teraphy) è un trattamento minimamente invasivo che combina farmaci fotosensibilizzanti, ossigeno e luce per uccidere le cellule tumorali. È un approccio selettivo con effetti collaterali minimi sui tessuti normali, che offre una promettente alternativa alla chemioterapia standard. Nonostante sia stata approvata per l’uso clinico 20 anni fa, la PDT trova ancora un uso limitato nella maggior parte dei tipi di cancro. Il progetto BIOnanoPDT, finanziato dall’UE, propone di incorporare la ftalocianina come farmaco fotosensibilizzante in nanoparticelle polimeriche biodegradabili funzionalizzate per colpire le cellule tumorali. Ciò contribuirà a risolvere i problemi associati a selettività, aggregazione e bassa solubilità in acqua dei farmaci fotosensibilizzanti, migliorando l’applicazione della PDT in ambito clinico.

Obiettivo

According to the World Health Organization cancer was responsible for approximated 9.6 million deaths in 2018 what is the reason of being one of the biggest civilizational health problem, just behind the heart diseases. The global objective of interdisciplinary BIOnanoPDT project is to develop novel biodegradable phthalocyanine (Pc)-polymeric nanoparticles (NPs) which enhance cancer photodynamic therapy (PDT).
Up to now, there is no ideal therapy for cancer treatment but among the others PDT presents several advantages, e.g. it is a selective treatment with less secondary effects than other therapies. This promising therapy combines three components: photosensitizer (PS), light and oxygen. 20 years ago PDT was approved by Food and Drug Admnistration as a clinical protocol for cancer treatment but it still have limitations to use it in all types of cancer. The development of new powerful PSs, which specifically target cancer cells, and can more deeply penetrate tissue allowing to treat large tumors is still a challenge.
Phthalocyanines (Pcs) are one of the most promising second generation PSs and meet many requirements for being ideal PSs. Unfortunately, very often Pcs are hydrophobic species and undergo self-aggregation in aqueous solutions, which drastically reduces their photosensitizing efficiency. In BIOnanoPDT project the limitations of Pcs will be overcame by tailoring their properties in terms of singlet oxygen generation and by incorporating them with polymer NPs which could improve their photophysical properties, selectivity for targeted tissues by surface modification, eliminate aggregation of the PSs and their low water solubility. Additionally, it can enhance the treatment by increasing the blood circulation and selective accumulation in tumor cells.
The BIOnanoPDT project will bring many innovations to the current cancer research by novel Pc-polymer NP hybrids for cancer PDT which will be an attractive alternative for conventional drugs.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Meccanismo di finanziamento

MSCA-IF -

Coordinatore

CENTRUM MATERIALOW POLIMEROWYCH IWEGLOWYCH POLSKA AKADEMIA NAUK*CMPIW PAN
Contributo netto dell'UE
€ 149 625,60
Indirizzo
UL. M CURIE SKLODOWSKIEJ 34
41 819 Zabrze
Polonia

Mostra sulla mappa

Regione
Makroregion południowy Śląskie Gliwicki
Tipo di attività
Organizzazioni di ricerca
Collegamenti
Costo totale
€ 149 625,60